We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+25.88%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$266M
AUM Growth
+$58.2M
Cap. Flow
+$10.2M
Cap. Flow %
3.84%
Top 10 Hldgs %
51.18%
Holding
88
New
23
Increased
18
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$6.17M
2
CEMI
Chembio diagnostics, Inc.
CEMI
+$5.47M
3
EVDY
Everyday Health, Inc.
EVDY
+$4.74M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.54M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.97M

Top Sells

Rank Stock Value
1
RRM
RR MEDIA LTD ORD SHS (ISR)
RRM
+$8M
2
FOLD
Amicus Therapeutics
FOLD
+$3.32M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.2M
4
MDVN
MEDIVATION, INC.
MDVN
+$3.02M
5
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$2.96M

Sector Composition

Rank Sector Weight
1 Healthcare 68.34%
2 Technology 2.54%
3 Industrials 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
Sarepta Therapeutics
SRPT
$1.68B
$3.07M 1.15%
50,000
-80,000
-62% -$2.42M
BMRN icon
27
BioMarin Pharmaceuticals
BMRN
$11.6B
$2.78M 1.04%
30,000
-34,000
-53% -$3.2M
PGNX
28
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$2.74M 1.03%
432,370
-16,515
-4% -$99.8K
BCRX icon
29
BioCryst Pharmaceuticals
BCRX
$2.24B
$2.44M 0.92%
+554,448
New +$2.21M
SRPT icon
30
CALL
Sarepta Therapeutics
SRPT
$1.68B
$2.44M 0.92%
39,700
-40,300
-50% -$1.22M
TSRO
31
DELISTED
TESARO, Inc.
TSRO
$2.27M 0.85%
22,700
-7,300
-24% -$682K
ASMB icon
32
Assembly Biosciences
ASMB
$503M
$2.27M 0.85%
26,184
+7,397
+39% +$571K
AERI
33
CALL
DELISTED
Aerie Pharmaceuticals
AERI
$2.25M 0.84%
+59,600
New +$1.31M
RDUS
34
DELISTED
Radius Health, Inc.
RDUS
$2.16M 0.81%
+40,000
New +$2.03M
GHDX
35
DELISTED
Genomic Health, Inc.
GHDX
$2.08M 0.78%
72,100
+23,300
+48% +$649K
DBVT
36
DBV Technologies
DBVT
$804M
$2.04M 0.77%
+5,626
New +$1.95M
ALR
37
DELISTED
Alere Inc
ALR
$1.95M 0.73%
+45,000
New +$1.84M
EPIX
38
DELISTED
ESSA Pharma
EPIX
$1.68M 0.63%
29,335
+823
+3% +$44K
ALIM
39
DELISTED
Alimera Sciences
ALIM
$1.45M 0.55%
64,955
– –
AGIO icon
40
Agios Pharmaceuticals
AGIO
$1.82B
$1.32M 0.5%
+25,000
New +$1.09M
ACAD icon
41
CALL
Acadia Pharmaceuticals
ACAD
$4.39B
$1.27M 0.48%
+40,000
New +$1.36M
SVA
42
DELISTED
Sinovac Biotech, Ltd
SVA
$1.21M 0.45%
204,358
+71,855
+54% +$423K
ATRC icon
43
AtriCure
ATRC
$1.97B
$1.05M 0.39%
66,186
-46,737
-41% -$718K
OTLK icon
44
Outlook Therapeutics
OTLK
$171M
$1.04M 0.39%
1,534
+13
+0.9% +$8.26K
AZN icon
45
AstraZeneca
AZN
$245B
$986K 0.37%
+15,000
New +$980K
MRTX
46
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$826K 0.31%
125,000
– –
AGEN
47
Agenus
AGEN
$326M
$748K 0.28%
+5,308
New +$609K
THC icon
48
Tenet Healthcare
THC
$20.1B
$743K 0.28%
+32,809
New +$854K
EHIC
49
DELISTED
eHi Car Services Limited
EHIC
$603K 0.23%
+58,827
New +$622K
CRBP icon
50
Corbus Pharmaceuticals
CRBP
$165M
$552K 0.21%
+2,710
New +$337K
1
2
3 4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2016 Portfolio in Review

As of Q3 2016, Acuta Capital Partners held 88 positions worth $266M, up 28% from $208M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Acuta Capital Partners deployed $10.2M of net new capital in Q3 2016, opening 23 new positions and adding to 18 existing holdings. Its largest new stake was Aerie Pharmaceuticals: 280,000 shares worth $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 73% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $3.32M trimmed.

  • Acuta Capital Partners's largest Q3 2016 buy was Aerie Pharmaceuticals: 280,000 shares worth $10.6M.
  • Acuta Capital Partners added most to Chembio diagnostics, Inc. in Q3 2016, an estimated $5.47M increase.
  • Acuta Capital Partners's biggest Q3 2016 reduction was Amicus Therapeutics, cutting an estimated $3.32M.
  • Acuta Capital Partners fully exited RR MEDIA LTD ORD SHS (ISR) in Q3 2016, selling an estimated $8M.
  • Acuta Capital Partners's ten largest holdings make up 51% of its $266M portfolio in Q3 2016.
  • Acuta Capital Partners opened 23 new positions and closed 21 in Q3 2016.
  • Acuta Capital Partners's portfolio value rose 28% quarter-over-quarter to $266M.

Based on Acuta Capital Partners's 13F filing for Q3 2016, filed 14 Nov 2016.